Publikationen, an denen er mitarbeitet FERNANDO ANTONIO RODRÍGUEZ DE FONSECA (82)

2023

  1. Antidepressant Medication Does Not Contribute to the Elevated Circulating Concentrations of Acylethanolamides Found in Substance Use Disorder Patients

    International Journal of Molecular Sciences, Vol. 24, Núm. 19

  2. Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder

    International journal of molecular sciences, Vol. 24, Núm. 11

  3. Associations of hypomagnesemia in patients seeking a first treatment of alcohol use disorder

    Drug and Alcohol Dependence, Vol. 245

  4. Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  5. Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder

    International Journal of Molecular Sciences, Vol. 24, Núm. 21

  6. Plasma concentrations of lysophosphatidic acid and the expression of its receptors in peripheral blood mononuclear cells are altered in patients with cocaine use disorders

    Translational Psychiatry, Vol. 13, Núm. 1

2022

  1. Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "diabesity"

    Journal of Medicinal Chemistry, Vol. 65, Núm. 7, pp. 5449-5461

  2. Gut microbiota and voluntary alcohol consumption

    Translational Psychiatry, Vol. 12, Núm. 1

  3. Niveles plasmáticos de midkina en pacientes con trastorno por uso de cocaína en abstinencia

    Adicciones: Revista de socidrogalcohol, Vol. 34, Núm. 4, pp. 273-277

  4. Seroprevalence of anti-SARS-CoV-2 IgG antibodies: relationship with COVID-19 diagnosis, symptoms, smoking, and method of transmission

    IJID Regions, Vol. 4, pp. 10-16

  5. Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder

    Biomedicines, Vol. 10, Núm. 5

2021

  1. Abrupt cessation of reboxetine along alcohol deprivation results in alcohol intake escalation after reinstatement of drinking

    Addiction Biology, Vol. 26, Núm. 3

  2. Evaluation of neurotrophic factors and education level as predictors of cognitive decline in alcohol use disorder

    Scientific Reports, Vol. 11, Núm. 1

  3. Sudden cessation of fluoxetine before alcohol drinking reinstatement alters microglial morphology and TLR4/inflammatory neuroadaptation in the rat brain

    Brain Structure and Function, Vol. 226, Núm. 7, pp. 2243-2264

  4. The immune system through the lens of alcohol intake and gut microbiota

    International Journal of Molecular Sciences, Vol. 22, Núm. 14

  5. Trastorno por uso de cocaína y depresión: Cuando el diagnóstico clínico no es suficiente

    Adicciones: Revista de socidrogalcohol, Vol. 33, Núm. 3, pp. 193-200

2020

  1. Cessation of fluoxetine treatment increases alcohol seeking during relapse and dysregulates endocannabinoid and glutamatergic signaling in the central amygdala

    Addiction Biology, Vol. 25, Núm. 5

  2. Cocaine-induced changes in CX3CL1 and inflammatory signaling pathways in the hippocampus: Association with IL1β

    Neuropharmacology, Vol. 162

  3. Plasma tryptophan and kynurenine pathway metabolites in abstinent patients with alcohol use disorder and high prevalence of psychiatric comorbidity

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 102

  4. Potential association of plasma lysophosphatidic acid (LPA) species with cognitive impairment in abstinent alcohol use disorders outpatients

    Scientific Reports, Vol. 10, Núm. 1